Mimetic Medicines
About Mimetic Medicines
Mimetic Medicines develops short lipidated peptidomimetics (SLiPs) designed to disrupt ion channel-scaffold protein complexes in peripheral pain nerves. These SLiPs selectively target nociceptors responsible for neuropathic pain signaling without crossing the blood-brain barrier. This mechanism offers a potentially disease-modifying approach to pain management with improved safety and tolerability compared to current CNS-acting therapies.
Mimetic Medicines develops short lipidated peptidomimetics (SLiPs) designed to disrupt ion channel-scaffold protein complexes in peripheral pain nerves. These SLiPs selectively target nociceptors responsible for neuropathic pain signaling without crossing the blood-brain barrier. This mechanism offers a potentially disease-modifying approach to pain management with improved safety and tolerability compared to current CNS-acting therapies.
What does Mimetic Medicines do?
Mimetic Medicines develops short lipidated peptidomimetics (SLiPs) designed to disrupt ion channel-scaffold protein complexes in peripheral pain nerves. These SLiPs selectively target nociceptors responsible for neuropathic pain signaling without crossing the blood-brain barrier. This mechanism offers a potentially disease-modifying approach to pain management with improved safety and tolerability compared to current CNS-acting therapies.
Where is Mimetic Medicines located?
Mimetic Medicines is based in Miami, United States.
When was Mimetic Medicines founded?
Mimetic Medicines was founded in 2023.
- Location
- Miami, United States
- Founded
- 2023
- Employees
- 4 employees